We discover 和 deliver innovative medicines that solve serious health issues 和 enhance people’s lives by unlocking the full potential of diverse 和 talented teams – 和 partners – to deliver today 和 into the future. We innovate with integrity 和 intention to advance long-term patient health 和 business resiliency. 这是我们对改善社会的承诺.
We strive to make a remarkable impact on patients 和 drive sustainable growth by consistently discovering 和 delivering innovative medicines that address serious health issues 和 enhance people’s lives. 2020年，我们实现了这一目标 12个新产品或适应症的批准或扩展. 其中包括风湿性关节炎的新疗法, moderate to severe plaque psoriasis 和 previously untreated chronic lymphocytic leukemia.
我们相信，每个需要我们药物的人都应该能够得到它们. Our patient assistance programs serve as an important safety net for patients who lack insurance or whose health plans limit coverage for our treatments. In 2020, 近15.5万名患者免费接受了十博10bet国际网页版的药物治疗 通过我们的病人援助项目.
我们相信有目的的工作能推动有意义的改变. We nurture diverse talent to solve the most complex challenges 和 create remarkable impact in people’s lives. 这就是我们致力于公平、平等和多样性的原因 & 包容基于我们的公司原则，拥抱多样性 & 包容性以及为什么我们还签署了三项承诺 CEO为多样性而行动 & 包含™ 承诺, 范例平价® 和 平等商业联盟法案. 2020年，49%的管理职位(经理级及以上)由女性担任.
我们不断努力改善世界各地患者的健康结果. We offer a wide range of disease 和 country-specific patient programs that provide meaningful, informative 和 empowering support to patients who have been prescribed AbbVie medicines. We also seek to underst和 the people’s perspective on living with their condition so that we can better support patients 和 customers now 和 into the future. 另外, we support independent educational grants 和 continuing medical education to ensure both physicians 和 patients have access to meaningful independent educational resources around new 和 emerging sciences 和 st和ards of care that contribute to improved health outcomes. 在2020年，我们达到了 超过1.100万名患者 和 超过177,000名卫生保健提供者 通过独立教育拨款.
我们承诺提供安全有效的服务, 通过健全的质量体系保证产品和药品的质量. 一旦我们的药物被批准上市, 我们维持一个强有力的药物警戒计划，以确保持续的安全. 我们定期监测安全信号，我们定期实现 不良事件的及时快速报告率超过98% 到你.S. 食品和药物管理局(FDA)和欧洲药品管理局(EMA).
